[go: up one dir, main page]

CO2022014726A2 - Anticuerpos anti-sea de muc1 - Google Patents

Anticuerpos anti-sea de muc1

Info

Publication number
CO2022014726A2
CO2022014726A2 CONC2022/0014726A CO2022014726A CO2022014726A2 CO 2022014726 A2 CO2022014726 A2 CO 2022014726A2 CO 2022014726 A CO2022014726 A CO 2022014726A CO 2022014726 A2 CO2022014726 A2 CO 2022014726A2
Authority
CO
Colombia
Prior art keywords
antibodies
muc1
sea antibodies
muc1 anti
sea
Prior art date
Application number
CONC2022/0014726A
Other languages
English (en)
Inventor
Daniel Rubinstein
Daniel Wreschner
Original Assignee
Univ Ramot
Biomodifying Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Biomodifying Llc filed Critical Univ Ramot
Publication of CO2022014726A2 publication Critical patent/CO2022014726A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invención proporciona anticuerpos monoclonales aislados que se unen al dominio SEA de MUC1. La invención se refiere, además, al uso de estos anticuerpos en métodos terapéuticos y de diagnóstico.
CONC2022/0014726A 2020-03-18 2022-10-18 Anticuerpos anti-sea de muc1 CO2022014726A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991077P 2020-03-18 2020-03-18
PCT/IL2021/050269 WO2021186427A1 (en) 2020-03-18 2021-03-11 Anti- muc1-sea antibodies

Publications (1)

Publication Number Publication Date
CO2022014726A2 true CO2022014726A2 (es) 2023-02-16

Family

ID=75439163

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014726A CO2022014726A2 (es) 2020-03-18 2022-10-18 Anticuerpos anti-sea de muc1

Country Status (19)

Country Link
US (1) US20230085269A1 (es)
EP (1) EP4087879A1 (es)
JP (1) JP2023517754A (es)
KR (1) KR20220161267A (es)
CN (1) CN115667312A (es)
AU (1) AU2021239078A1 (es)
BR (1) BR112022018629A2 (es)
CA (1) CA3171531A1 (es)
CL (1) CL2022002520A1 (es)
CO (1) CO2022014726A2 (es)
CR (1) CR20220523A (es)
CU (1) CU20220055A7 (es)
DO (1) DOP2022000193A (es)
EC (1) ECSP22080687A (es)
IL (1) IL296572A (es)
MX (1) MX2022011553A (es)
PE (1) PE20230602A1 (es)
PH (1) PH12022552445A1 (es)
WO (1) WO2021186427A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202436343A (zh) * 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Muc1與cd16a抗體以及其使用方法
WO2024183637A1 (en) * 2023-03-03 2024-09-12 Beigene Switzerland Gmbh Muc1 antibodies and methods of use
US20250041437A1 (en) 2023-07-31 2025-02-06 Sun Pharma Advanced Research Company Limited Humanized muc1 antibody and antibody drug conjugate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE527285T1 (de) * 2005-01-28 2011-10-15 Univ Ramot Anti-muc1-alpha-beta-antikörper
AU2018238165C1 (en) * 2017-03-21 2021-03-18 Peptron, Inc. Antibody binding specifically to MUC1 and use thereof

Also Published As

Publication number Publication date
CN115667312A (zh) 2023-01-31
PH12022552445A1 (en) 2023-11-20
CU20220055A7 (es) 2023-06-13
EP4087879A1 (en) 2022-11-16
PE20230602A1 (es) 2023-04-10
CR20220523A (es) 2023-01-23
AU2021239078A1 (en) 2022-08-11
CL2022002520A1 (es) 2023-03-10
IL296572A (en) 2022-11-01
ECSP22080687A (es) 2022-12-30
WO2021186427A1 (en) 2021-09-23
BR112022018629A2 (pt) 2023-03-07
US20230085269A1 (en) 2023-03-16
MX2022011553A (es) 2023-01-04
DOP2022000193A (es) 2023-03-23
JP2023517754A (ja) 2023-04-26
CA3171531A1 (en) 2021-09-23
KR20220161267A (ko) 2022-12-06

Similar Documents

Publication Publication Date Title
CO2022014726A2 (es) Anticuerpos anti-sea de muc1
CL2020002305A1 (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1
ECSP19078429A (es) Anticuerpos anti-trem2 y métodos para utilizarlos
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
PE20200757A1 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
CL2021000258A1 (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
EA201892716A1 (ru) Антитела к фактору свертывания xi
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA202190235A1 (ru) Антитела к cd33 и способы их применения
CO2021000046A2 (es) Anticuerpos de unión a vista a ph ácido
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
BR112022004831A2 (pt) Anticorpos que se ligam a vista em ph ácido
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
BR112021010634A2 (pt) Anticorpos antiperiostina e usos dos mesmos
MX2023009434A (es) Anticuerpos contra cd112r y usos de los mismos.
CO2024003042A2 (es) Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos
AR122237A1 (es) Anticuerpos anti-sortilina y métodos para su uso
EA202092279A1 (ru) Антитела к mica и/или micb и их применение
EA201992324A1 (ru) Анти-trem2 антитела и способы их применения
EA202090586A2 (ru) Триспецифичные связывающие молекулы и способы их применения